A direct comparison of intravascular ultrasound and quantitative coronary arteriography: Implications for measures of atherosclerosis as clinical surrogates

Circulation

Volumn 115, Issue 14, 2007, Pages 1824-1826

  Brown, B Greg ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Atherosclerosis; Editorials; Imaging; Lipids; Lipoproteins

Indexed keywords

AMLODIPINE; ATORVASTATIN; ENALAPRIL; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN;

ANGIOCARDIOGRAPHY; ARTERY DISEASE; ATHEROSCLEROSIS; CLINICAL TRIAL; COMPARATIVE STUDY; DIAGNOSTIC PROCEDURE; DISEASE SEVERITY; EDITORIAL; ETHICS; HUMAN; IMAGING; INTRAVASCULAR ULTRASOUND; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; RISK FACTOR; THROMBOSIS;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CLINICAL TRIALS; COHORT STUDIES; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; DISEASE PROGRESSION; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 34247171185     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.106.689968     Document Type: Editorial

References (20)

1. Brown BG, Bolson E, Frimer M, Dodge HT. Quantitative coronary arteriography: estimation of dimensions, hemodynamic resistance, and atheroma mass of coronary artery lesions using the arteriogram and digital computation. Circulation. 1977;55:329-337.
2. Brown BG, Hillger LA, Lewis C, Zhao XQ, Sacco D, Bisson B, Fisher L. A maximum-confidence approach for measuring progression and regression of coronary artery disease in clinical trials. Circulation. 1993; 87(suppl II):II-66-II-73.
3. Chambless LE, Heiss G, Folsom AR, Rosamond W, Szklo M, Sharrett AR, Clegg LX. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) study, 1987-1993. Am J Epidemiol. 1997;146:483-494.
4. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins [published correction appears in Circulation. 2004;110:3615]. Circulation. 2004;110:3512-3517.
5. Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Chaplin WF, Muntwyler J, Viles-Gonzalez JF, Weinberger J, Smith DA, Mizsei G, Badimon JJ. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol. 2005;46:106-112.
6. Kasaoka S, Tobis JM, Akiyama T, Reimers B, Di Mario C, Wong ND, Colombo A. Angiographic and intravascular ultrasound predictors of in-stent restenosis. J Am Coll Cardiol. 1998;32:1630-1635.
7. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN; REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering on progression of coronary atherosclerosis. JAMA. 2004;291:1071-1080.
8. Berry C, L'Allier PL, Grégoire J, Lespérance J, Levesque S, Ibrahim R, Tardif J-C. Comparison of intravascular ultrasound and quantitative coronary angiography for the assessment of coronary artery disease progression. Circulation. 2007;115:1851-1857.
9. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid-lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 1993;87:1781-1791.
10. Waters D, Craven TE, Lesperance J. Prognostic significance of progression of coronary atherosclerosis. Circulation. 1993;87:1067-1075.
11. Zhao XQ, Yuan C, Hatsukami TS, Frechette EH, Kang XJ, Maravilla KR, Brown BG. Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI. Arterioscler Thromb Vasc Biol. 2001;21:1623-1629.
12. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J. 1993;69:377-381.
13. Kragel AH, Reddy SG, Wittes JT, Roberts WC. Morphometric analysis of the composition of atherosclerotic plaques in the four major epicardial coronary arteries in acute myocardial infarction and in sudden coronary death. Circulation. 1989;80:1747-1756.
14. von Birgelen C, Hartmann M, Mintz GS, van Houwelingen KG, Deppermann N, Schmermund A, Bose D, Eggebrecht H, Neumann T, Gossl M, Wieneke H, Erbel R. Relationship between cardiovascular risk as predicted by established risk scores versus plaque progression as measured by serial intravascular ultrasound in left main coronary arteries. Circulation. 2004;110:1579-1585.
15. Tuzcu EM, Kapadia SR, Sachar R, Ziada KM, Crowe TD, Feng J, Magyar WA, Hobbs RE, Starling RC, Young JB, McCarthy P, Nissen SE. Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation. J Am Coll Cardiol. 2005;45:1538-1542.
16. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316:1371-1375.
17. Brown BG, Stukovsky KH, Zhao XQ. Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials. Curr Opin Lipidol. 2006;17:631-636.
18. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol EJ; CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217-2225.
19. Nissen SE, Nicholls SJ, Sipahi I, Nissen SE, Nicholls SJ, Sipahi I; ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295:1556-1565.
20. Brown BG, Zhao XQ. Is intravascular ultrasound the gold standard surrogate for clinically relevant atherosclerosis progression? J Amer Coll Cardiol 2007;49:933-938.